{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T19:46:41Z","timestamp":1794944801182,"version":"4.9.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T00:00:00Z","timestamp":1754352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T00:00:00Z","timestamp":1754352000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006390","name":"University of Lausanne","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006390","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Retin Vitr"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>The aim of the study is to investigate the short- and long-term effects of delayed intravitreal anti-VEGF injections (IVI) for macular edema (ME) in retinal vein occlusion (RVO) patients during the first wave of the COVID-19 pandemic.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>This is a retrospective observational study analyzing a cohort of patients followed at the medical retina department of the Jules Gonin Eye Hospital. During the COVID-19 lockdown, treatment for patients with ME secondary to RVO was deferred due to emergency federal dispositions. The impact on best corrected visual acuity (BCVA) and on OCT changes (i.e. central subfield thickness (CST), intraretinal fluid (IRF), and subretinal fluid (SRF)) were assessed at several time points before and after the lockdown over a 2-year period. The OCT parameters were assessed by the mean of an artificial intelligence (AI) software (Discovery, RetinAI).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>A total of 64 patients were included in the study. BCVA significantly decreased following a mean treatment delay of 10 weeks. However, BCVA returned to baseline levels after 6 months, with no significant differences observed after 2-years of follow-up. OCT analysis revealed an increase in CST, IRF and SRF following the treatment delay, which decreased and return to pre-lockdown values after 3 months. No significant differences in OCT parameters were observed at the two-year follow-up.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>The results of our study suggest that delaying IVI for RVO patients during the COVID-19 lockdown resulted in a temporary decline in BCVA and a recurrence of ME. However, these effects were not sustained long term, as both BCVA and ME control returned to baseline levels by 6 months, with no significant changes observed at the two-year follow-up.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s40942-025-00717-x","type":"journal-article","created":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T11:07:59Z","timestamp":1754392079000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Short and long-term impact of intravitreal anti-VEGF therapy interruption in retinal vein occlusion during the COVID-19 pandemic: functional outcomes and AI-based fluid analysis of macular edema"],"prefix":"10.1186","volume":"11","author":[{"given":"Emmanuelle","family":"Moret","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Cattaneo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adham","family":"Elwakil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Montesel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattia","family":"Tommasoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara M.","family":"Eandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,5]]},"reference":[{"issue":"1","key":"717_CR1","doi-asserted-by":"publisher","first-page":"010427","DOI":"10.7189\/jogh.09.010427","volume":"9","author":"P Song","year":"2019","unstructured":"Song P, Xu Y, Zha M, Zhang Y, Rudan I. Global epidemiology of retinal vein occlusion: a systematic review and meta-analysis of prevalence, incidence, and risk factors. J Glob Health. 2019;9(1):010427.","journal-title":"J Glob Health"},{"issue":"2","key":"717_CR2","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1097\/APO.0000000000000598","volume":"12","author":"F Romano","year":"2023","unstructured":"Romano F, Lamanna F, Gabrielle PH, Teo KYC, Battaglia Parodi M, Iacono P, et al. Update on retinal vein occlusion. Asia-Pac J Ophthalmol. 2023;12(2):196\u2013210.","journal-title":"Asia-Pac J Ophthalmol"},{"key":"717_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.preteyeres.2014.04.001","volume":"41","author":"SS Hayreh","year":"2014","unstructured":"Hayreh SS. Ocular vascular occlusive disorders: natural history of visual outcome. Prog Retin Eye Res. 2014;41:1\u201325.","journal-title":"Prog Retin Eye Res"},{"issue":"6","key":"717_CR4","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1016\/j.ophtha.2010.01.060","volume":"117","author":"RL McIntosh","year":"2010","unstructured":"McIntosh RL, Rogers SL, Lim L, Cheung N, Wang JJ, Mitchell P, et al. Natural history of central retinal vein occlusion: an evidence-based systematic review. Ophthalmology. 2010;117(6):1113\u2013e112315.","journal-title":"Ophthalmology"},{"issue":"Suppl 2","key":"717_CR5","doi-asserted-by":"publisher","first-page":"ii24","DOI":"10.1136\/bjophthalmol-2014-305305","volume":"98","author":"G Trichonas","year":"2014","unstructured":"Trichonas G, Kaiser PK. Optical coherence tomography imaging of macular oedema. Br J Ophthalmol. 2014;98(Suppl 2):ii24\u201329.","journal-title":"Br J Ophthalmol"},{"issue":"7","key":"717_CR6","first-page":"CD009510","volume":"7","author":"Z Shalchi","year":"2020","unstructured":"Shalchi Z, Mahroo O, Bunce C, Mitry D. Anti-vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion. Cochrane Database Syst Rev. 2020;7(7):CD009510.","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"717_CR7","first-page":"CD007325","volume":"2014","author":"T Braithwaite","year":"2014","unstructured":"Braithwaite T, Nanji AA, Lindsley K, Greenberg PB. Anti-vascular endothelial growth factor for macular oedema secondary to central retinal vein occlusion. Cochrane Database Syst Rev. 2014;2014(5):CD007325.","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"717_CR8","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.ophtha.2013.08.012","volume":"121","author":"JF Korobelnik","year":"2014","unstructured":"Korobelnik JF, Holz FG, Roider J, Ogura Y, Simader C, Schmidt-Erfurth U, et al. Intravitreal Aflibercept injection for macular edema resulting from central retinal vein occlusion: One-Year results of the phase 3 GALILEO study. Ophthalmology. 2014;121(1):202\u20138.","journal-title":"Ophthalmology"},{"key":"717_CR9","doi-asserted-by":"publisher","first-page":"248","DOI":"10.3389\/fphar.2015.00248","volume":"6","author":"CBM Platania","year":"2015","unstructured":"Platania CBM, Di Paola L, Leggio GM, Romano GL, Drago F, Salomone S, et al. Molecular features of interaction between VEGFA and anti-angiogenic drugs used in retinal diseases: a computational approach. Front Pharmacol. 2015;6:248.","journal-title":"Front Pharmacol"},{"issue":"8","key":"717_CR10","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1097\/01.iae.0000242842.14624.e7","volume":"26","author":"N Ferrara","year":"2006","unstructured":"Ferrara N, Damico L, Shams N, Lowman H, Kim R. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina Phila Pa. 2006;26(8):859\u201370.","journal-title":"Retina Phila Pa"},{"issue":"2","key":"717_CR11","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s10456-011-9249-6","volume":"15","author":"N Papadopoulos","year":"2012","unstructured":"Papadopoulos N, Martin J, Ruan Q, Rafique A, Rosconi MP, Shi E, et al. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF trap, Ranibizumab and bevacizumab. Angiogenesis. 2012;15(2):171\u201385.","journal-title":"Angiogenesis"},{"issue":"6","key":"717_CR12","doi-asserted-by":"publisher","first-page":"e1199","DOI":"10.1111\/aos.15068","volume":"100","author":"K Nanji","year":"2022","unstructured":"Nanji K, Khan M, Khalid MF, Xie JS, Sarohia GS, Phillips M, et al. Treat-and-extend regimens of anti-vascular endothelial growth factor therapy for retinal vein occlusions: a systematic review and meta-analysis. Acta Ophthalmol (Copenh). 2022;100(6):e1199\u2013208.","journal-title":"Acta Ophthalmol (Copenh)"},{"key":"717_CR13","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.ajo.2021.01.027","volume":"227","author":"JF Korobelnik","year":"2021","unstructured":"Korobelnik JF, Larsen M, Eter N, Bailey C, Wolf S, Schmelter T, et al. Efficacy and safety of intravitreal Aflibercept Treat-and-Extend for macular edema in central retinal vein occlusion: the CENTERA study. Am J Ophthalmol. 2021;227:106\u201315.","journal-title":"Am J Ophthalmol"},{"issue":"6","key":"717_CR14","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1007\/s00417-020-04703-x","volume":"258","author":"JF Korobelnik","year":"2020","unstructured":"Korobelnik JF, Loewenstein A, Eldem B, Joussen AM, Koh A, Lambrou GN, et al. Guidance for anti-VEGF intravitreal injections during the COVID-19 pandemic. Graefes Arch Clin Exp Ophthalmol Albrecht Von Graefes Arch Klin Exp Ophthalmol. 2020;258(6):1149\u201356.","journal-title":"Graefes Arch Clin Exp Ophthalmol Albrecht Von Graefes Arch Klin Exp Ophthalmol"},{"issue":"4","key":"717_CR15","doi-asserted-by":"publisher","first-page":"100096","DOI":"10.1016\/j.apjo.2024.100096","volume":"13","author":"JI Lim","year":"2024","unstructured":"Lim JI, Rachitskaya AV, Hallak JA, Gholami S, Alam MN. Artificial intelligence for retinal diseases. Asia-Pac J Ophthalmol. 2024;13(4):100096.","journal-title":"Asia-Pac J Ophthalmol"},{"key":"717_CR16","doi-asserted-by":"publisher","unstructured":"Apostolopoulos S, De Zanet S, Ciller C, Wolf S, Sznitman R, Pathological OCT. Retinal Layer Segmentation Using Branch Residual U-Shape Networks. In: Descoteaux M, Maier-Hein L, Franz A, Jannin P, Collins DL, Duchesne S, editors. Medical Image Computing and Computer Assisted Intervention\u2013\u2009MICCAI 2017 [Internet]. Cham: Springer International Publishing; 2017 [cited 2025 Apr 27]. pp. 294\u2013301. (Lecture Notes in Computer Science; vol. 10435). Available from: https:\/\/link.springer.com\/https:\/\/doi.org\/10.1007\/978-3-319-66179-7_34","DOI":"10.1007\/978-3-319-66179-7_34"},{"key":"717_CR17","doi-asserted-by":"publisher","unstructured":"Mousavi S, Garjani A, Elwakil A, Brock LP, Dherse A, Forestier E et al. Cohort Builder: A Software Pipeline for Generating Patient Cohorts with Predetermined Baseline Characteristics from Medical Records and Raw Ophthalmic Imaging Data. In: Mantas J, Hasman A, Demiris G, Saranto K, Marschollek M, Arvanitis TN, editors. Studies in Health Technology and Informatics [Internet]. IOS Press; 2024 [cited 2025 Apr 27]. Available from: https:\/\/ebooks.iospress.nlhttps:\/\/doi.org\/10.3233\/SHTI240613","DOI":"10.3233\/SHTI240613"},{"key":"717_CR18","unstructured":"Swiss Federal Council. Ordinance on measures to combat the coronavirus (COVID-19). Available at: https:\/\/www.fedlex.admin.ch\/eli\/cc\/2020\/141\/en"},{"issue":"1","key":"717_CR19","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1177\/1120672120962032","volume":"31","author":"A Carnevali","year":"2021","unstructured":"Carnevali A, Giannaccare G, Gatti V, Scuteri G, Randazzo G, Scorcia V. Intravitreal injections during COVID-19 outbreak: Real-world experience from an Italian tertiary referral center. Eur J Ophthalmol. 2021;31(1):10\u20132.","journal-title":"Eur J Ophthalmol"},{"issue":"6","key":"717_CR20","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.jfo.2020.04.019","volume":"43","author":"L Kodjikian","year":"2020","unstructured":"Kodjikian L. [How to approach intravitreal injections during this COVID-19 pandemic?]. J Fr Ophtalmol. 2020;43(6):539\u201340.","journal-title":"J Fr Ophtalmol"},{"issue":"4","key":"717_CR21","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1167\/tvst.10.4.17","volume":"10","author":"I Mantel","year":"2021","unstructured":"Mantel I, Mosinska A, Bergin C, Polito MS, Guidotti J, Apostolopoulos S, et al. Automated quantification of pathological fluids in neovascular Age-Related macular degeneration, and its repeatability using deep learning. Transl Vis Sci Technol. 2021;10(4):17.","journal-title":"Transl Vis Sci Technol"},{"issue":"7","key":"717_CR22","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1007\/s00417-021-05549-7","volume":"260","author":"A Navarrete","year":"2022","unstructured":"Navarrete A, Vofo B, Matos K, Rivera A, Levy J. The detrimental effects of delayed intravitreal anti-VEGF therapy for treating retinal pathology: lessons from a forced test-case. Graefes Arch Clin Exp Ophthalmol Albrecht Von Graefes Arch Klin Exp Ophthalmol. 2022;260(7):2201\u20138.","journal-title":"Graefes Arch Clin Exp Ophthalmol Albrecht Von Graefes Arch Klin Exp Ophthalmol"},{"issue":"4","key":"717_CR23","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1097\/IAE.0000000000003369","volume":"42","author":"A Montesel","year":"2022","unstructured":"Montesel A, Gigon A, Giacuzzo C, Mantel I, Eandi CM. TREATMENT DEFERRAL DURING COVID-19 LOCKDOWN: functional and anatomical impact on patients with neovascular Age-Related macular degeneration. Retina Phila Pa. 2022;42(4):634\u201342.","journal-title":"Retina Phila Pa"},{"issue":"1","key":"717_CR24","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1177\/24741264221136637","volume":"7","author":"W Song","year":"2023","unstructured":"Song W, Kanyo E, Bastian R, Singh RP, Rachitskaya AV. Visual acuity in patients requiring intravitreal injections: Short-Term and Long-Term effects of delay in care. J Vitreoretin Dis. 2023;7(1):20\u20136.","journal-title":"J Vitreoretin Dis"},{"key":"717_CR25","doi-asserted-by":"publisher","unstructured":"Koss MJ, Pfister M, Rothweiler F, Michaelis M, Cinatl J, Schubert R et al. Comparison of cytokine levels from undiluted vitreous of untreated patients with retinal vein occlusion. Acta Ophthalmol (Copenh) [Internet]. 2012 Mar [cited 2025 Jul 9];90(2). Available from: https:\/\/onlinelibrary.wiley.com\/doi\/https:\/\/doi.org\/10.1111\/j.1755-3768.2011.02292.x","DOI":"10.1111\/j.1755-3768.2011.02292.x"},{"issue":"1","key":"717_CR26","first-page":"42","volume":"22","author":"H Noma","year":"2008","unstructured":"Noma H, Funatsu H, Yamasaki M, Tsukamoto H, Mimura T, Sone T, et al. Aqueous humour levels of cytokines are correlated to vitreous levels and severity of macular oedema in branch retinal vein occlusion. Eye Lond Engl. 2008;22(1):42\u20138.","journal-title":"Eye Lond Engl"},{"issue":"1","key":"717_CR27","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.ophtha.2008.09.034","volume":"116","author":"H Noma","year":"2009","unstructured":"Noma H, Funatsu H, Mimura T, Harino S, Hori S. Vitreous levels of interleukin-6 and vascular endothelial growth factor in macular edema with central retinal vein occlusion. Ophthalmology. 2009;116(1):87\u201393.","journal-title":"Ophthalmology"},{"issue":"1","key":"717_CR28","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.ophtha.2013.08.038","volume":"121","author":"PA Campochiaro","year":"2014","unstructured":"Campochiaro PA, Sophie R, Pearlman J, Brown DM, Boyer DS, Heier JS, et al. Long-term outcomes in patients with retinal vein occlusion treated with ranibizumab: the RETAIN study. Ophthalmology. 2014;121(1):209\u201319.","journal-title":"Ophthalmology"},{"issue":"3","key":"717_CR29","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1007\/s10792-017-0538-y","volume":"38","author":"MA Khan","year":"2018","unstructured":"Khan MA, Mallika V, Joshi D. Comparison of immediate versus deferred intravitreal bevacizumab in macular oedema due to branch retinal vein occlusion: a pilot study. Int Ophthalmol. 2018;38(3):943\u20139.","journal-title":"Int Ophthalmol"},{"issue":"12","key":"717_CR30","doi-asserted-by":"publisher","first-page":"2587","DOI":"10.1016\/j.ophtha.2012.06.037","volume":"119","author":"DL Epstein","year":"2012","unstructured":"Epstein DL, Algvere PV, Von Wendt G, Seregard S, Kvanta A. Benefit from bevacizumab for macular edema in central retinal vein occlusion: Twelve-Month results of a prospective, randomized study. Ophthalmology. 2012;119(12):2587\u201391.","journal-title":"Ophthalmology"},{"issue":"5","key":"717_CR31","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1016\/j.ophtha.2016.01.011","volume":"123","author":"M Larsen","year":"2016","unstructured":"Larsen M, Waldstein SM, Boscia F, Gerding H, Mon\u00e9s J, Tadayoni R, et al. Individualized Ranibizumab regimen driven by stabilization criteria for central retinal vein occlusion: Twelve-Month results of the CRYSTAL study. Ophthalmology. 2016;123(5):1101\u201311.","journal-title":"Ophthalmology"},{"issue":"3","key":"717_CR32","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.ajo.2012.09.026","volume":"155","author":"DM Brown","year":"2013","unstructured":"Brown DM, Heier JS, Clark WL, Boyer DS, Vitti R, Berliner AJ, et al. Intravitreal Aflibercept injection for macular edema secondary to central retinal vein occlusion: 1-year results from the phase 3 COPERNICUS study. Am J Ophthalmol. 2013;155(3):429\u2013e4377.","journal-title":"Am J Ophthalmol"},{"issue":"5","key":"717_CR33","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1038\/s41433-022-02007-4","volume":"36","author":"L Nicholson","year":"2022","unstructured":"Nicholson L, Talks SJ, Amoaku W, Talks K, Sivaprasad S. Retinal vein occlusion (RVO) guideline: executive summary. Eye. 2022;36(5):909\u201312.","journal-title":"Eye"},{"issue":"1","key":"717_CR34","doi-asserted-by":"publisher","first-page":"16974","DOI":"10.1038\/s41598-024-67925-7","volume":"14","author":"C Agata","year":"2024","unstructured":"Agata C, Aoki S, Kitamoto K, Azuma K, Fujino R, Inoue T, et al. Time to initiate anti-vascular endothelial growth factor therapy and visual outcome in central retinal vein occlusion. Sci Rep. 2024;14(1):16974.","journal-title":"Sci Rep"},{"issue":"6","key":"717_CR35","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1016\/j.survophthal.2022.08.002","volume":"67","author":"JHB Im","year":"2022","unstructured":"Im JHB, Jin YP, Chow R, Dharia RS, Yan P. Delayed anti-VEGF injections during the COVID-19 pandemic and changes in visual acuity in patients with three common retinal diseases: A systematic review and meta-analysis. Surv Ophthalmol. 2022;67(6):1593\u2013602.","journal-title":"Surv Ophthalmol"},{"issue":"3","key":"717_CR36","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/s41433-022-01960-4","volume":"37","author":"JC Liu","year":"2023","unstructured":"Liu JC, Alsaloum P, Iyer AI, Kaiser PM, Singh RP. Consequences of anti-vascular endothelial growth factor treatment lapse in patients with retinal vein occlusion. Eye. 2023;37(3):453\u20138.","journal-title":"Eye"},{"issue":"1","key":"717_CR37","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1177\/2474126420943418","volume":"5","author":"JR Abraham","year":"2021","unstructured":"Abraham JR, Boss J, Babiuch AS, Singh RP, Srivastava S, Reese J, et al. Longitudinal assessment of ellipsoid zone mapping parameters in retinal venous occlusive disease with associated macular edema. J Vitreoretin Dis. 2021;5(1):40\u20135.","journal-title":"J Vitreoretin Dis"},{"issue":"1","key":"717_CR38","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s40662-024-00397-y","volume":"11","author":"MW Lee","year":"2024","unstructured":"Lee MW, Jun JH, Seong HJ. Longitudinal changes in each retinal layer thickness in patients with non-ischemic central retinal vein occlusion. Eye Vis. 2024;11(1):29.","journal-title":"Eye Vis"},{"issue":"7","key":"717_CR39","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1016\/j.oret.2021.05.002","volume":"5","author":"M Gallardo","year":"2021","unstructured":"Gallardo M, Munk MR, Kurmann T, De Zanet S, Mosinska A, Karagoz IK, et al. Machine learning can predict Anti-VEGF treatment demand in a Treat-and-Extend regimen for patients with neovascular AMD, DME, and RVO associated macular edema. Ophthalmol Retina. 2021;5(7):604\u201324.","journal-title":"Ophthalmol Retina"},{"issue":"1","key":"717_CR40","doi-asserted-by":"publisher","first-page":"13623","DOI":"10.1038\/s41598-024-64047-y","volume":"14","author":"D Jee","year":"2024","unstructured":"Jee D, Park S, Kwon Jwoo. Subretinal fluid in macular edema secondary to branch retinal vein occlusion. Sci Rep. 2024;14(1):13623.","journal-title":"Sci Rep"},{"issue":"12","key":"717_CR41","doi-asserted-by":"publisher","first-page":"3540","DOI":"10.3390\/jcm11123540","volume":"11","author":"H Sasajima","year":"2022","unstructured":"Sasajima H, Zako M, Maeda R, Murotani K, Ishida H, Ueta Y. Foveal intraretinal fluid localization affects the visual prognosis of branch retinal vein occlusion. J Clin Med. 2022;11(12):3540.","journal-title":"J Clin Med"}],"container-title":["International Journal of Retina and Vitreous"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40942-025-00717-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40942-025-00717-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40942-025-00717-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T18:49:07Z","timestamp":1757357347000},"score":1,"resource":{"primary":{"URL":"https:\/\/journalretinavitreous.biomedcentral.com\/articles\/10.1186\/s40942-025-00717-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,5]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["717"],"URL":"https:\/\/doi.org\/10.1186\/s40942-025-00717-x","relation":{},"ISSN":["2056-9920"],"issn-type":[{"value":"2056-9920","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,5]]},"assertion":[{"value":"10 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study received approval from the local institutional review board and ethical committee (CER-VD n. 2021\u2009\u2212\u200901612) and adhered to the principles of the Declaration of Helsinki. All patients had given informed consent. The study was approved by the Ethics Committee of the Swiss Federal Department of Health for retrospective data analysis.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Patients had given their informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"92"}}